Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Howard

Showing results (371-380 of 429) with videos related to

Pageof 43
Sort By:
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
The Lancet. Neurology|October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Diabetes|January 1, 1982
Metabolic and underlying causes of diabetes mellitusG M Grodsky, C E Anderson, D L Coleman, et al.
JCI Insight|May 18, 2018
TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25Elizabeth A Thompson, Sebastian Ols, Kazutoyo Miura, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 3, 2024
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)James F Howard, Tuan Vu, George Li, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Infection and Immunity|June 22, 2011
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsionJoanne M Lumsden, Sathit Pichyangkul, Utaiwan Srichairatanakul, et al.
Pageof 43

Showing results (371-380 of 429) with videos related to

Sort By:
Pageof 43
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
The Lancet. Neurology|October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Diabetes|January 1, 1982
Metabolic and underlying causes of diabetes mellitusG M Grodsky, C E Anderson, D L Coleman, et al.
JCI Insight|May 18, 2018
TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25Elizabeth A Thompson, Sebastian Ols, Kazutoyo Miura, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 3, 2024
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)James F Howard, Tuan Vu, George Li, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Infection and Immunity|June 22, 2011
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsionJoanne M Lumsden, Sathit Pichyangkul, Utaiwan Srichairatanakul, et al.
Pageof 43